Back to company

EvodiaBio ApS: Financial statements 2023

CVR: 42569283

EvodiaBio ApS (CVR 42569283) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -9,941,780 and a net result of DKK -14,056,555 compared with DKK -6,304,639 the year before. Equity amounted to DKK 23,625,867. The solvency ratio was 83.9%. The company had 10 employees in the financial year.

Gross Profit
-9,941,780 kr.
Profit/Loss
-14,056,555 kr.
Equity
23,625,867 kr.
Total Assets
28,165,796 kr.
Employees
10

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023--9.9 mio.-14.1 mio.23.6 mio.10
2022--2.9 mio.-6.3 mio.37.7 mio.7

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

EvodiaBio ApS: The 2022 annual report is outMay 17, 2023

EvodiaBio ApS has published its annual report for 2022. Gross profit came to DKK -2,943,103, and the net result was DKK -6,304,639.

About EvodiaBio ApS

EvodiaBio ApS is a Danish company of the type Anpartsselskab based in Rødovre, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Camilla Benedicte Kloss Fenneberg. The company's owners include Jarne Elleholm, BII Holdings A/S and FormanBiotech Holding ApS. In 2025, the company reported a gross profit of DKK -8,437,110 and a net result of DKK -26,798,122 compared with DKK -21,106,598 the year before. Equity amounted to DKK 68,626,121.

Other financial years